Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12848310 | 0.81 | CYP2D6 (0.47) | CYP2D6SMN1; SMN2DRD2ALDH1A1CYP3A4 | |
| SCHEMBL12396368 | 0.79 | CYP2D6 (0.34) | CYP2D6SMN1; SMN2 | |
| SCHEMBL24134156 | 0.78 | S1PR1 (0.36) | DRD2 | |
| SCHEMBL11570592 | 0.78 | — | — | |
| SCHEMBL4420326 | 0.78 | CYP2D6 (0.34) | CYP2D6SMN1; SMN2DRD2ALDH1A1CYP3A4 | |
| SCHEMBL25730471 | 0.76 | KDM2B (0.34) | — | |
| SCHEMBL23514830 | 0.75 | OPRM1 (0.39) | CYP2D6SMN1; SMN2DRD2ALDH1A1CYP3A4 | |
| SCHEMBL3419547 | 0.74 | CYP2D6 (0.42) | CYP2D6SMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL11929538 | 0.73 | KMT2A (0.44) | CYP2D6ALDH1A1 | |
| SCHEMBL15223351 | 0.73 | KMT2A (0.44) | CYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210353610-A1 | SMALL MOLECULE MENIN INHIBITORS | SERVIER PHARMACEUTICALS LLC | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353610-A1 | SMALL MOLECULE MENIN INHIBITORS | MEN1, BRCA1, KRAS | CYP2D6 4026/4885SMN1; SMN2 422/4885DRD2 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.